|Dr. Noubar B. Afeyan Ph.D.||Co-Founder, Chairman & Member of Technology Advisory Board||101.27k||N/A||1963|
|Mr. Stéphane Bancel||CEO & Director||2.67M||N/A||1973|
|Dr. Lorence H. Kim||Chief Financial Officer||1.22M||N/A||1974|
|Dr. Stephen Hoge||Pres||N/A||N/A||1976|
|Jennifer Lee||Chief Accounting Officer||N/A||N/A||N/A|
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.